A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03755128 |
|
Recruitment Status :
Recruiting
First Posted : November 27, 2018
Last Update Posted : May 17, 2022
|
Sponsor:
Momenta Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Momenta Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary purpose of the study is to characterize the current standard of care, clinical course, and outcomes of pregnant women and their offspring at high risk for early onset severe hemolytic disease of the fetus and newborn (EOS-HDFN).
| Condition or disease | Intervention/treatment |
|---|---|
| Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN) Erythroblastosis, Fetal | Other: No intervention |
| Study Type : | Observational |
| Estimated Enrollment : | 15 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | A Multicenter, Prospective Observational Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn |
| Actual Study Start Date : | January 16, 2019 |
| Estimated Primary Completion Date : | February 27, 2024 |
| Estimated Study Completion Date : | February 27, 2024 |
| Group/Cohort | Intervention/treatment |
|---|---|
| Pregnant women and their offspring from current pregnancy |
Other: No intervention
No investigational drugs will be administered as part of the study |
Primary Outcome Measures :
- Percentage of Participants With Live Birth at or After Gestational Age (GA) Week 32 Without Intrauterine Transfusion (IUT) [ Time Frame: GA Week 32 through GA Week 37 ]
Secondary Outcome Measures :
- Percentage of Participants With Live Birth [ Time Frame: Up to approximately GA Week 37 ]
- Percentage of Participants at GA Week 24 Without an IUT [ Time Frame: Week 24 ]
- GA at First IUT [ Time Frame: Up to approximately GA Week 37 ]
- Number of IUTs Required [ Time Frame: Up to approximately GA Week 37 ]
- Percentage of Participants With Fetal Hydrops [ Time Frame: Post-Birth through Age 3 Months ]
- Percentage of Neonates Requiring Phototherapy [ Time Frame: Post-Birth through Age 3 Months ]
- Percentage of Neonates Requiring Exchange Transfusions [ Time Frame: Post-Birth through Age 3 Months ]
- Number of days of phototherapy required by neonate [ Time Frame: Post-Birth through Age 3 Months ]
- Percentage of Neonates Requiring Simple Transfusions in the First 3 Months of Life [ Time Frame: Post-Birth through Age 3 Months ]
- Number of Simple Transfusions Required by Neonate in the First 3 Months of Life [ Time Frame: Post-Birth through Age 3 Months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Participants must have an obstetrical history of severe fetal anemia, hydrops, or stillbirth related to hemolytic disease of the fetus and newborn, have alloantibody titers for anti-D ≥32 or anti-Kell titers ≥4, and be currently pregnant with an antigen-positive fetus. Eligible women may enter the study at any time during the current pregnancy prior to delivery.
Criteria
Pregnant female participants must be ≥18 years of age with an estimated Gestational Age of ≥ 8 weeks; not currently pregnant with multiples (twins or more); and no other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03755128
Contacts
| Contact: Study Contact | 844-434-4210 | Participate-In-This-Study@its.jnj.com |
Locations
Show 19 study locations
Sponsors and Collaborators
Momenta Pharmaceuticals, Inc.
Investigators
| Study Director: | Momenta General Queries | Momenta Pharmaceuticals, Inc. |
| Responsible Party: | Momenta Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT03755128 |
| Other Study ID Numbers: |
CR109067 MOM-M281-103 ( Other Identifier: Momenta Pharmaceuticals, Inc. ) |
| First Posted: | November 27, 2018 Key Record Dates |
| Last Update Posted: | May 17, 2022 |
| Last Verified: | May 2022 |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Momenta Pharmaceuticals, Inc.:
|
Hemolytic disease of the fetus and newborn (HDFN) Erythroblastosis, Fetal Early onset severe hemolytic disease of the fetus and newborn (EOS-HDFN) M281 Pregnant Women |
Additional relevant MeSH terms:
|
Erythroblastosis, Fetal Hemolysis Pathologic Processes Fetal Diseases |
Pregnancy Complications Hematologic Diseases Infant, Newborn, Diseases Immune System Diseases |